LA Carey

1.3k total citations
49 papers, 560 citations indexed

About

LA Carey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, LA Carey has authored 49 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in LA Carey's work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (18 papers) and Breast Cancer Treatment Studies (17 papers). LA Carey is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (18 papers) and Breast Cancer Treatment Studies (17 papers). LA Carey collaborates with scholars based in United States, Italy and United Kingdom. LA Carey's co-authors include Eric P. Winer, P. Kelly Marcom, Charles M. Perou, William Irvin, Hope S. Rugo, Madlyn Ferraro, Xiaping He, Emily Burrows, EP Winer and SM Tolaney and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

LA Carey

45 papers receiving 538 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
LA Carey United States	12	439	307	146	117	62	49	560
Alessio Schirone Italy	12	242 0.6×	144 0.5×	173 1.2×	124 1.1×	40 0.6×	22	432
Shuiping Gao China	13	229 0.5×	194 0.6×	99 0.7×	263 2.2×	74 1.2×	28	539
Silvia Bessi Italy	9	452 1.0×	354 1.2×	142 1.0×	106 0.9×	44 0.7×	14	566
Chongyang Ren China	10	193 0.4×	160 0.5×	88 0.6×	149 1.3×	52 0.8×	33	363
Jutta Groos Germany	6	292 0.7×	125 0.4×	146 1.0×	101 0.9×	44 0.7×	7	384
Jianguo Lai China	13	159 0.4×	248 0.8×	126 0.9×	303 2.6×	34 0.5×	42	511
Zhanhong Chen China	13	173 0.4×	259 0.8×	104 0.7×	216 1.8×	31 0.5×	50	448
Ashutosh Lodhi United States	11	613 1.4×	454 1.5×	177 1.2×	157 1.3×	19 0.3×	19	744
Cristina Hernándo Spain	13	196 0.4×	178 0.6×	114 0.8×	188 1.6×	20 0.3×	46	414
Françoise Beltjens France	10	305 0.7×	161 0.5×	120 0.8×	82 0.7×	34 0.5×	32	469

Countries citing papers authored by LA Carey

Since Specialization

Citations

This map shows the geographic impact of LA Carey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by LA Carey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites LA Carey more than expected).

Fields of papers citing papers by LA Carey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by LA Carey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by LA Carey. The network helps show where LA Carey may publish in the future.

Co-authorship network of co-authors of LA Carey

This figure shows the co-authorship network connecting the top 25 collaborators of LA Carey. A scholar is included among the top collaborators of LA Carey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with LA Carey. LA Carey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manich, C. Saura, LA Carey, J. O’Shaughnessy, et al.. (2025). 297O Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3. ESMO Open. 10. 104869–104869.

Ligibel, JA, Anna Weiss, Tracy E. Crane, et al.. (2024). 1817MO Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial. Annals of Oncology. 35. S1078–S1078. 1 indexed citations

Rossi, Giovanna, Étienne Brain, Amylou C. Dueck, et al.. (2022). 90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6). Annals of Oncology. 33. S162–S163. 1 indexed citations

Carey, LA, et al.. (2021). Understanding and treating triple-negative breast cancer. UNC Libraries. 76 indexed citations

Tanioka, Maki, Chuanwen Fan, LA Carey, et al.. (2017). Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. Cancer Research. 77(4_Supplement). S3–5. 1 indexed citations

Berry, DA, Bhupender Singh, C. Cirrincione, et al.. (2016). Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Research. 76(4_Supplement). S2–5. 51 indexed citations

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

Berry, DA, Bhupender Singh, Constance Cirrincione, et al.. (2013). Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research. 73(24_Supplement). S5–1. 39 indexed citations

Marcom, P. Kelly, Anna C. Snavely, Kim T. Blackwell, et al.. (2013). Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC). Cancer Research. 73(24_Supplement). P2–16. 1 indexed citations

10.

Anders, Carey K., Rachita Nanda, Kim T. Blackwell, et al.. (2011). TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM).. Journal of Clinical Oncology. 29(15_suppl). TPS127–TPS127. 3 indexed citations

11.

Gucalp, Ayca, SM Tolaney, SJ Isakoff, et al.. (2011). TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS122–TPS122. 4 indexed citations

12.

Isakoff, SJ, Paul E. Goss, Erica L. Mayer, et al.. (2011). TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.. Journal of Clinical Oncology. 29(15_suppl). 1025–1025. 30 indexed citations

13.

Ligibel, JA, HJ Burstein, KD Miller, et al.. (2011). OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.. Cancer Research. 71(24_Supplement). OT3–2. 3 indexed citations

14.

Bardia, Aditya, Lori J. Sokoll, J. N. Ingle, et al.. (2010). Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study.. Journal of Clinical Oncology. 28(15_suppl). 1001–1001. 2 indexed citations

15.

Adamo, Bárbara, Emily Burrows, Karen Fritchie, et al.. (2010). Abstract P1-14-01: Phosphatidylinositol 3-Kinase (PI3K) Pathway Activation in Breast Cancer Brain Metastases. Cancer Research. 70(24_Supplement). P1–14. 1 indexed citations

16.

Meng, Huan Xin, Emily Burrows, Karen Fritchie, et al.. (2010). The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases.. Journal of Clinical Oncology. 28(15_suppl). 1027–1027. 1 indexed citations

17.

Kommareddy, A., Robert J. Crowder, Fei Gao, et al.. (2009). A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.. Cancer Research. 69(2_Supplement). 16–16. 6 indexed citations

18.

Carey, LA, Hope S. Rugo, P. Kelly Marcom, et al.. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1009–1009. 133 indexed citations

19.

Carey, LA. (2007). Triple-negative (basal-like) breast cancer: a new entity. Breast Cancer Research. 9(S1). 6 indexed citations

20.

Simpson, Dennis A., Hayley D. McKeen, Lynda Sawyer, et al.. (2006). Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis. 27(12). 2519–2527. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact